Compare Honest Company Inc (HNST) vs Novavax Inc (NVAX) Price & Performance

HNST trades at $3.87, up 1.04% today, with a bullish technical signal from moving averages. The company reported Q1 2026 EPS of $0.01, meeting estimates, but has missed expectations in two of the last three quarters. Revenue declined to $371.32 million in 2025 from $378 million in 2024, with a net loss of $15.69 million. Positive cash flow from operations of $15.12 million and record gross margins near 34% highlight operational improvements amid challenges.

The outlook remains mixed; analyst consensus is cautious with 30% buy ratings. Upside potential exists from gross margin expansion and cost controls, but risks include persistent net losses, competitive pressures in personal care, and reliance on retail channel growth. Investor sentiment is neutral, pending sustained profitability and revenue stabilization in 2026.

Novavax (NVAX) trades at $7.86, down 4.26% on the day amid a bearish technical signal, though it has beaten earnings estimates for the last three quarters. The company reported $1.12 billion in revenue for 2025 with a net income of $440.30 million, yet faces negative shareholder equity and cash flow challenges. Recent news highlights stock volatility and shareholder dissent at the AGM, while analyst consensus remains largely bullish with a $14.00 price target.

The outlook for NVAX hinges on sustaining profitability and managing cash burn, with significant upside potential per analyst targets but substantial risks from negative equity, competitive pressures, and reliance on vaccine demand. Investors must weigh the high volatility and financial health concerns against the optimistic Wall Street ratings.